Development of megestrol acetate solid dispersion nanoparticles for enhanced oral delivery by using a supercritical antisolvent process.
In the present study, solid dispersion nanoparticles with a hydrophilic polymer and surfactant were developed using the supercritical antisolvent (SAS) process to improve the dissolution and oral absorption of megestrol acetate. The physicochemical properties of the megestrol acetate solid dispersion nanoparticles were characterized using scanning electron microscopy, differential scanning calorimetry, powder X-ray diffraction, and a particle-size analyzer. The dissolution and oral bioavailability of the nanoparticles were also evaluated in rats. The mean particle size of all solid dispersion nanoparticles that were prepared was <500 nm. Powder X-ray diffraction and differential scanning calorimetry measurements showed that megestrol acetate was present in an amorphous or molecular dispersion state within the solid dispersion nanoparticles. Hydroxypropylmethyl cellulose (HPMC) solid dispersion nanoparticles significantly increased the maximum dissolution when compared with polyvinylpyrrolidone K30 solid dispersion nanoparticles. The extent and rate of dissolution of megestrol acetate increased after the addition of a surfactant into the HPMC solid dispersion nanoparticles. The most effective surfactant was Ryoto sugar ester L1695, followed by D-α-tocopheryl polyethylene glycol 1000 succinate. In this study, the solid dispersion nanoparticles with a drug:HPMC:Ryoto sugar ester L1695 ratio of 1:2:1 showed >95% rapid dissolution within 30 minutes, in addition to good oral bioavailability, with approximately 4.0- and 5.5-fold higher area under the curve (0-24 hours) and maximum concentration, respectively, than raw megestrol acetate powder. These results suggest that the preparation of megestrol acetate solid dispersion nanoparticles using the supercritical antisolvent process is a promising approach to improve the dissolution and absorption properties of megestrol acetate.
College of Pharmacy, Pusan National University, Yongin, South Korea.
Eun-Sol
ES
Ha
Dong-A ST Co Ltd, Yongin, South Korea.
Jeong-Soo
JS
Kim
College of Pharmacy, Kyungsung University, Busan, South Korea.
In-Hwan
IH
Baek
College of Pharmacy, Pusan National University, Yongin, South Korea.
Jin-Wook
JW
Yoo
College of Pharmacy, Pusan National University, Yongin, South Korea.
Yunjin
Y
Jung
College of Pharmacy, Pusan National University, Yongin, South Korea.
Hyung Ryong
HR
Moon
College of Pharmacy, Pusan National University, Yongin, South Korea.
Min-Soo
MS
Kim
D000284:Administration, Oral; D000818:Animals; D019540:Area Under Curve; D001682:Biological Availability; D002152:Calorimetry, Differential Scanning; D002626:Chemistry, Pharmaceutical; D025924:Chromatography, Supercritical Fluid; D018360:Crystallography, X-Ray; D065347:Hypromellose Derivatives / Q000737:chemistry; D007408:Intestinal Absorption; D008297:Male; D019290:Megestrol Acetate / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D008855:Microscopy, Electron, Scanning; D053758:Nanoparticles; D036103:Nanotechnology; D011092:Polyethylene Glycols / Q000737:chemistry; D011205:Povidone / Q000737:chemistry; D033362:Powder Diffraction; D045167:Progesterone Congeners / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D017207:Rats, Sprague-Dawley; D012995:Solubility; D013501:Surface-Active Agents / Q000737:chemistry; D013678:Technology, Pharmaceutical / Q000379:methods*; D014810:Vitamin E / Q000031:analogs & derivatives / Q000737:chemistry
D045167:Progesterone Congeners; D013501:Surface-Active Agents; D014810:Vitamin E; D065347:Hypromellose Derivatives; D011092:Polyethylene Glycols; D011205:Povidone; C014225:tocophersolan; D019290:Megestrol Acetate
bioavailability; dissolution; megestrol acetate; supercritical technology